Menu Search
Equities

Somnomed Ltd

SOMNF:PKC

Somnomed Ltd

Actions
  • Price (USD)0.1739
  • Today's Change0.00 / 0.00%
  • Shares traded1.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 01 2024 13:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SomnoMed Limited is an Australia-based company engaged in producing and selling devices for the oral treatment of sleep-related disorders. It provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. It is focused on the commercialization of the SomnoDent Mandibular Advancement Splint and other oral devices for sleep related disorders. Its segments include North America, Europe, Asia Pacific, CORE, and RSS. Its SomnoDent product line includes SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, SomnoDent Fusion, Herbst Advance Elite and Herbst Advance. Its SomMorning Repositioner is designed to help return their mandible back to its pre-treatment centric position. Its SomnoBrux Michigan splint is a custom fit, acrylic splint (dental guard) for upper teeth designed to protect the teeth from grinding and scraping during Bruxism. It also offers SomTabs, which are cleaning tablets that are developed to clean oral appliances.

  • Revenue in AUD (TTM)91.68m
  • Net income in AUD-12.24m
  • Incorporated1987
  • Employees300.00
  • Location
    Somnomed LtdLevel 3, 20 Clarke St, Crows NestSYDNEY 2065AustraliaAUS
  • Phone+61 29467-0400
  • Fax+61 29467-0467
  • Websitehttps://somnomed.com/en/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.